Sydney Jennings

Assess your knowledge of fiber targets, fruit and vegetable serving goals, and microbiome guidance in the 2025–2030 Dietary Guidelines.

Deucravacitinib (Sotyktu) is the first TYK2 inhibitor approved for the treatment of PsA.

Five trials presented at AAAAI 2026 highlight new therapies and prevention strategies for hereditary angioedema, atopic dermatitis, asthma, and chronic urticaria.

Large study links DASH and other healthy diets

New FDA approvals span swallowable obesity balloon, dupilumab for fungal sinusitis, oral desmopressin, updated menopause labels, and sildenafil film.

New data highlight digital dementia risk scores, plasma p-tau217 prediction, and patient-centered endpoints in Alzheimer disease research.

The FDA issued 30 warning letters to telehealth firms for false or misleading claims about compounded GLP-1 products, citing illegal marketing practices.

ACP updates RSV vaccine guidance: adults 75+ get a one-time protein subunit shot; higher-risk ages 60–74 may consider it to prevent hospitalization.

Review key updates to the Dietary Guidelines for Americans to support patient counseling, nutritional assessments, and evidence-based interventions.

AAAAI 2026: In LIBERTY-CSU CUPID, dupilumab reduced ISS7 and UAS7 at 24 weeks across BMI, angioedema, and gender subgroups in CSU.

FDA approves DESMODA, a ready-to-use desmopressin acetate oral solution, enabling precise titration for central diabetes insipidus with key hyponatremia warnings.

FDA approves dupilumab for allergic fungal rhinosinusitis ages 6+, cutting sinus blockage, polyps and smell loss while sharply reducing repeat surgery and steroid use.

In a phase 2 trial in China, UBT251 led to up to 19.7% mean weight loss at 24 weeks vs 2.0% with placebo in adults with overweight or obesity.

In the REDEFINE 4 trial, CagriSema led to 23% weight loss at 84 weeks but did not demonstrate noninferiority to tirzepatide 15 mg in adults with obesity.

In 142 000 adults, adding Galleri to standard screening reduced stage IV diagnoses over time in a prespecified group of 12 cancers, according to new data.

SMART trial finds clesrovimab protects high-risk children in a second RSV season, with consistent safety and fewer RSV-related hospitalizations.

Real-world data show GSK’s Arexvy is linked to 75.6% lower hospitalization risk in adults ≥60, with reduced CV events and COPD exacerbations.

Data show 44-week durable clinical remission in ulcerative colitis and endoscopic response in Crohn disease with duvakitug, a TL1A-targeting monoclonal antibody now in phase 3 trials.

New phase 3 data show single-inhaler triple therapy boosts FEV₁ and cuts severe asthma attacks for patients uncontrolled on ICS–LABA.

FDA updates menopause hormone therapy labels, dropping boxed warning claims on heart disease, breast cancer, and dementia after evidence review.

Calling physicians “providers” undermines ethics and professionalism, an American College of Physicians position paper argues.

Adults with obesity achieved up to 12.1% mean weight loss with oral ribupatide vs placebo in a 26-week phase 2 trial.

Booster-backed speed-of-processing brain training links to lower Alzheimer disease and dementia diagnoses, suggesting modest computer exercises may delay decline.

Three-year BE HEARD data show bimekizumab sustains HS lesion clearance, cuts draining tunnels, and improves severity and quality of life.

FDA insulin updates, new obesity drug data, vaccine hesitancy strategies, and depression screening insights are featured in this week’s episode.

FDA clears a dissolvable sildenafil oral film for erectile dysfunction, offering discreet, water-free dosing and strong phase 3 results ahead of 2026 launch.

Researchers found that 58% of infants with atopic dermatitis achieved a 75% improvement in EASI-75 at week 4 with once-daily roflumilast cream 0.05%.

A new study reveals icotrokinra's comparable efficacy to existing therapies, offering hope for treatment-refractory patients facing resistance challenges.

The FDA delays approval of Anaphylm, a sublingual epinephrine film for anaphylaxis, citing administration and human factors study deficiencies.

GRAIL advances cancer detection with FDA application for Galleri, a groundbreaking blood test aimed at early detection of multiple cancers.